The combined administration of daniplestim and mpl ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression
Open Access
- 1 May 1998
- journal article
- the effects-of-mpl-ligand-in-animal-model
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 16 (S1) , 143-154
- https://doi.org/10.1002/stem.5530160717
Abstract
This study evaluated the ability of daniplestim, a high affinity interleukin 3 receptor agonist, to enhance the hematopoietic response of Mpl ligand (Mpl-L) administration in nonhuman primates following severe, radiation-induced myelosuppression. Rhesus monkeys were total body x-irradiated (TBI) to 600 cGy, midline tissue dose. Beginning on day 1 post-TBI, animals were s. c. administered daniplestim (100 μg/kg bid; n = 4), Mpl-L (10 μg/kg qd; n = 3), daniplestim (100 μg/kg bid) plus Mpl-L (10 μg/kg qd) (n = 4) or 0.1% autologous serum (AS) (n = 11) for 18 days. CBCs were monitored for 60 d after TBI. The duration of thrombocytopenia (platelet count; PLT p =.01), Mpl-L (3.0 d, p =.003) and the coadministered daniplestim/Mpl-L (1.3 d, p =.001) compared to controls (10.4 d). As monotherapy Mpl-L but not daniplestim significantly improved the PLT nadir (21,000/μl, p =.023 and 5,000/μl, p =.266, respectively) compared to the control (3,000/μl). The combined administration of daniplestim and Mpl-L significantly improved the PLT nadir (28,000/μl, p =.007) compared to both the control cohort (3,000/μl) and the daniplestim only cohort (5,000/μl, p =.043). Recovery of PLT to preirradiation values occurred earlier in the daniplestim only (d 21) or the daniplestim/Mpl-L cohorts (d 18) than in the Mpl-L only or control cohorts (d 28, d 29, respectively). The administration of daniplestim or Mpl-L alone neither shortened the duration of neutropenia (ANCp =.001 and 50/μl, p =.093, respectively) compared to the controls (8/μl). Coadministration of daniplestim and Mpl-L significantly improved the ANC nadir (196/μl, p =.001) compared to either the AS- or the monotherapy-treated cohorts. Also the duration of neutropenia observed in the As-controls (16.2 d) was significantly reduced in the daniplestim/Mpl-L cohort (10.8 d, p =.002). The combined administration of daniplestim and Mpl-L significantly improved hematopoietic recovery and further enhanced the stimulatory effect of cytokine monotherapy, as well as reducing clinical support requirements after radiation-induced bone marrow myelosuppression.Keywords
This publication has 59 references indexed in Scilit:
- Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatinBlood, 1994
- Comparative effects of in vivo treatment using interleukin-11 and stem cell factor on reconstitution in mice after bone marrow transplantationBlood, 1993
- Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized miceBlood, 1993
- Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and plateletsBlood, 1993
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture.Proceedings of the National Academy of Sciences, 1991
- GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATIONThe Lancet, 1989
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced MyelosuppressionNew England Journal of Medicine, 1988
- EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPYThe Lancet, 1988
- Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic SyndromesNew England Journal of Medicine, 1987